On November 10, 2021, the Minister of Health refused to reassess its decision that Janssen’s esketamine hydrochloride product (SPRAVATO) was not an “innovative drug” and therefore not entitled to data protection. As...more
Healthcare entities should assess whether Federal Law No. 2 of 2019 applies to their practices and plan for compliance. On 6 February 2019, the President of the United Arab Emirates (UAE) in conjunction with the UAE...more